5325232025-12-065325232025-12-062025-12-06iso4217:INRxbrli:pureBiocon LimitedBIOCONNewAcquisition (including agreement to acquire)2025-12-062025-12-06Biocon Limited ('the Company')Listed Entity (self)Biocon Biologics Limited ('BBL')295400000008310000000184910000000true2025-12-062025-12-06true2025-12-31trueBiocon Biologics Limited is a material subsidiary of Biocon Limitedtrue2025-12-31Pharmaceutical industryThe Strategy Committee, which was constituted by the Board in May 2025, after careful consideration of key parameters such as strategic alignment, sectoral dynamics, shareholder value creation, and other relevant factors, concluded that a full integration of BBL and the Company, through the acquisition of minority stakes in BBL represents the most efficient and value-accretive approach. This integration enabling combination of BBL and the Company’s business, will simplify the corporate structure, enable a larger balance sheet and unified capital allocation strategy to maximize value for all stakeholders. Additionally, it has potential to deliver operational synergies by consolidating group resources and harness strengths across complementary portfolio, commercial and manufacturing infrastructure to increase scale and market reach.NAtrueThe acquisition of equity shares of BBL by the Company, will be completed on or before March 31, 2026, subject to the approval of shareholders of the Company and receipt of in-principle approval from the stock exchanges.Cash and Shares695000000000.75BBL was incorporated in India on June 8, 2016, with an objective to set up Greenfield biosimilar biologics facilities. BBL, an unlisted material subsidiary of Biocon Limited, is a unique, fully integrated global biosimilars company committed to transforming healthcare and lives. Capitalizing on its “lab-to-market” capabilities, the company serves millions of patients across 120+ countries by enabling affordable access to high-quality biosimilars. BBL leverages cutting-edge science, innovative technology platforms, global-scale manufacturing capabilities, and world-class quality systems to reduce the cost of biological therapeutics while improving healthcare outcomes. The company has commercialized 10 biosimilars globally and maintains a robust development pipeline of 20+ biosimilar assets spanning diabetes, oncology, immunology, ophthalmology, and other chronic therapeutic segments. BBL has achieved several industry “firsts” — for example, approval of its interchangeable biosimilar insulins in the United States — and remains focused on advancing patient health, societal well-being, and environmental sustainability in line with global ESG and UN Sustainable Development Goals (SDGs). Last 3 years turnover (in Rs. Mn): • FY23: Rs. 20,923.83 Mn. • FY24: Rs. 30,932.50 Mn. • FY25: Rs. 29,543 Mn.202220232092000000020232024309300000002024202529540000000India